BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1835625)

  • 21. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
    Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
    J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Lauer SJ; Camitta BM; Leventhal BG; Mahoney DH; Shuster JJ; Adair S; Casper JT; Civin CI; Graham M; Kiefer G
    Cancer; 1993 May; 71(9):2854-61. PubMed ID: 8467463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sinusoidal Obstruction Syndrome During Maintenance Therapy for Acute Lymphoblastic Leukemia With 6-Mercaptopurine and Methotrexate: A Pediatric Case Report.
    McNerney KO; Vasquez JC; Kent MW; McNamara JM
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):e454-e455. PubMed ID: 28085749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
    Koren G; Langevin AM; Olivieri N; Giesbrecht E; Zipursky A; Greenberg M
    Am J Dis Child; 1990 Oct; 144(10):1135-7. PubMed ID: 2403095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
    Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
    J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV; Avramis VI
    Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why more 6-mercaptopurine?
    Kamen BA
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):12-4. PubMed ID: 1780746
    [No Abstract]   [Full Text] [Related]  

  • 30. Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism.
    Al-Ghobashy MA; Hassan SA; Abdelaziz DH; Elhosseiny NM; Sabry NA; Attia AS; El-Sayed MH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1038():88-94. PubMed ID: 27802917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine.
    Dervieux T; Hancock M; Evans W; Pui CH; Relling MV
    Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-kinetics and biochemical pharmacology of methotrexate and 6-mercaptopurine in human malignant T-lymphoblasts.
    Bökkerink JP; De Abreu RA; Stet EH; Damen FJ
    Klin Padiatr; 1992; 204(4):293-8. PubMed ID: 1518268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
    Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y
    Cancer Chemother Pharmacol; 1996; 37(6):525-30. PubMed ID: 8612305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia.
    Zou Y; Mei D; Yuan J; Han J; Xu J; Sun N; He H; Yang C; Zhao L
    Int J Nanomedicine; 2021; 16():1127-1141. PubMed ID: 33603372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.
    Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB
    J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
    Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
    J Clin Oncol; 2017 May; 35(15):1730-1736. PubMed ID: 28339328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine.
    Estlin EJ
    Cancer Treat Rev; 2001 Dec; 27(6):351-63. PubMed ID: 11908928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.
    Zaza G; Cheok M; Yang W; Panetta JC; Pui CH; Relling MV; Evans WE
    Blood; 2005 Sep; 106(5):1778-85. PubMed ID: 15905191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells.
    Bastian L; Einsiedel HG; Henze G; Seeger K; Shalapour S
    Leukemia; 2011 Feb; 25(2):359-61. PubMed ID: 21072050
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.